RBC Capital Sticks to Their Sell Rating for Healius Limited (PGZ)

Wong-Pan covers the Healthcare sector, focusing on stocks such as Resmed, CSL, and Cochlear . According to TipRanks, Wong-Pan has an average return of -2.0% and a 45.90% success rate on recommended stocks.

Currently, the analyst consensus on Healius Limited is a Moderate Sell with an average price target of €0.27.

Based on Healius Limited’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$688.1 million and a GAAP net loss of A$30.4 million. In comparison, last year the company earned a revenue of A$662.3 million and had a GAAP net loss of A$12.8 million

RBC Capital Sticks to Their Sell Rating for Healius Limited (PGZ)

Related reading

Jarden upgrades Healius Limited (PGZ) to a Hold

ALS (CPBLF) Gets a Buy from Macquarie

RBC Capital Sticks to Its Hold Rating for Pandora A/S (0NQC)

RBC Capital Reaffirms Their Buy Rating on SGH (9SG0)

ALS (CPBLF) Gets a Buy from Ord Minnett

EchoIQ Limited (EIQ) was downgraded to a Hold Rating at Bell Potter